Tylosin Market Report 2026

The tylosin market size has grown strongly in recent years. It will grow from $0.79 billion in 2025 to $0.83 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to growth of commercial livestock farming, widespread bacterial infections in animals, established efficacy of macrolide antibiotics, expansion of veterinary healthcare services, rising global meat consumption.

The tylosin market size is expected to see steady growth in the next few years. It will grow to $1 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing demand for protein-rich diets, growth in commercial animal farming, rising investments in veterinary care, expansion of animal health regulations, increasing adoption of preventive veterinary treatments. Major trends in the forecast period include rising demand for veterinary antibiotics, growing use in livestock disease management, increasing focus on animal health and welfare, expansion of poultry and swine farming, higher monitoring of antibiotic usage in animals.

The rise in meat production is anticipated to fuel the expansion of the tylosin market in the future. Meat production involves the breeding, slaughtering, and processing of livestock to yield meat for human use. This uptick stems from rising consumer demand for protein-rich diets, fueled by evolving nutritional trends. The tylosin market aids this growth in animal farming by promoting herd wellness via targeted treatment of respiratory and gastrointestinal bacterial diseases. For instance, in July 2024, the Department for Environment Food and Rural Affairs - a UK government body - reported that total animal feed output reached 29,397 units in 2022, climbing to 31,128 units in 2023. Thus, surging meat production is propelling the tylosin market forward.

The growth of the veterinary pharmaceutical sector is anticipated to boost the tylosin market in the future. The veterinary pharmaceutical industry encompasses the development, production, and distribution of medications, vaccines, and health products tailored to prevent, treat, and control diseases in animals. This sector's expansion stems mainly from rising pet ownership, which fuels demand for sophisticated animal health solutions and veterinary care. The veterinary pharmaceutical industry's growth bolsters the tylosin market by increasing the need for potent antimicrobial therapies that sustain animal health and productivity. For instance, in February 2025, the Competition and Markets Authority (CMA), a UK government body, reported that consumer spending on veterinary and other pet services reached approximately $7.84 in 2023. Thus, the expansion of the veterinary pharmaceutical industry is propelling the tylosin market forward.

The expansion and modernization of livestock farming are anticipated to boost the tylosin market in the future. Modernization in livestock farming involves integrating cutting-edge technologies, enhanced management techniques, and streamlined production methods to improve animal welfare, output, and long-term viability in farming activities. This growth and modernization stem mainly from rising consumer demand for premium animal-derived products, prompting farmers to embrace innovative practices, technologies, and optimized management approaches. Tylosin aids livestock operations by preserving animal health and efficiency via targeted control of bacterial infections, fostering more effective and eco-friendly farming. For instance, in January 2024, the Government Accountability Office - a U.S. government agency - reported that 27% of U.S. farms and ranches implemented precision agriculture techniques for crop or livestock management in 2023. Thus, the advancement and modernization of livestock farming are fueling tylosin market growth.

Major companies operating in the tylosin market are Zoetis Inc., Elanco Animal Health Inc., Ceva Santé Animale, Phibro Animal Health Corporation, Huvepharma AD, Vetoquinol S.A., Norbrook Inc., Shandong Lukang Pharmaceutical Co. Ltd., Qilu Animal Health Products Co. Ltd., Hebei Veyong Animal Pharmaceutical, Apeloa Pharmaceutical Co. Ltd., Suanfarma SA, AdvaCare Pharma, Ningxia Tairui Pharmaceutical Co. Ltd., Pucheng Chia Tai Biochemistry Co. Ltd., Anhui Sinotech Industrial, Rochem International Inc., Vetgen Healthcare Pvt. Ltd., Sunvet Pharma Private Ltd., Nestlife Science Pvt. Ltd.

North America was the largest region in the tylosin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tylosin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tylosin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the tylosin market by increasing the cost of imported active pharmaceutical ingredients and veterinary grade formulations used in animal health applications. These effects are most pronounced in animal feed additive and injectable drug segments, particularly in regions that depend on international supply chains for raw materials. Rising tariff related costs have contributed to higher treatment expenses for livestock producers and commercial farming operations. This has influenced purchasing decisions across poultry, swine, and cattle sectors. However, tariffs are also encouraging domestic api production, localized veterinary drug manufacturing, and stronger regional supply resilience over the long term.

The tylosin market research report is one of a series of new reports that provides tylosin market statistics, including tylosin industry global market size, regional shares, competitors with a tylosin market share, detailed tylosin market segments, market trends and opportunities, and any further data you may need to thrive in the tylosin industry. This tylosin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tylosin, a macrolide-class antibiotic, is commonly employed in veterinary medicine to address diverse bacterial infections in animals, especially livestock like cattle, swine, and poultry, as well as companion animals such as dogs and cats. This essential medication plays a key role in veterinary care by treating bacterial infections in animals, supporting the health and well-being of livestock and pets.

The primary forms of tylosin products include tylosin tartrate, tylosin phosphate, and various others. Tylosin tartrate serves as a common variant of the antibiotic tylosin, widely applied in veterinary medicine for managing bacterial infections in livestock. It finds use in areas like animal feed additives, animal medications, and additional purposes, and is available via hospital pharmacies, retail drug stores, pharmacies, and online suppliers.

The tylosin market consists of sales of oral powders, premixes, water-soluble powders, and injectable solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.